All In Biotech

NDA 218591 · Novartis

Entresto Sprinkle

Sacubitril, Valsartan · Oral · Angiotensin 2 Receptor Blocker

Last checked: Nov 19, 2026Latest source record: Apr 12, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2024

Apr 12, 2024

Approved uses

1

Original approval plus efficacy supplements

Registered trials

181

44 Phase 3, 23 recruiting

FAERS reports

116,184

59,720 serious, 14,200 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: FETAL TOXICITY When pregnancy is detected, discontinue ENTRESTO as soon as possible (5.1) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus (5.1) WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue ENTRESTO as soon as possible. ( 5.1 ) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. ( 5.1 )

What it is approved for

From the label in effect Jul 6, 2026.

ENTRESTO is a combination of sacubitril, a neprilisin inhibitor, and valsartan, an angiotensin II receptor blocker, and is indicated: to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. ( 1.1 ) for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. ENTRESTO reduces NT-proBNP and is expected to improve cardiovascular outcomes. ( 1.2 ) 1.1 Adult Heart Failure ENTRESTO is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. LVEF is a variable measure, so use clinical judgment in deciding whom to treat [see Clinical Studies (14.1)] . 1.2 Pediatric Heart Failure ENTRESTO is indicated for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. ENTRESTO reduces NT-proBNP and is expected to improve cardiovascular outcomes.

Mechanism: ENTRESTO contains a neprilysin inhibitor, sacubitril, and an angiotensin receptor blocker, valsartan. ENTRESTO inhibits neprilysin (neutral endopeptidase; NEP) via LBQ657, the active metabolite of the prodrug sacubitril, and blocks the angiotensin II type-1 (AT 1 ) receptor via valsartan. The cardiovascular and renal effects of ENTRESTO in heart failure patients are attributed to the increased levels of peptides that are degraded by neprilysin, such as natriuretic peptides, by LBQ657, and the simultaneous inhibition of the effects of angiotensin II by valsartan. Valsartan inhibits the effects...

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • ENTRESTO SPRINKLE · SACUBITRIL 6MG; VALSARTAN 6MG · CAPSULE, PELLETS, ORAL · Prescription
  • ENTRESTO SPRINKLE · SACUBITRIL 15MG; VALSARTAN 16MG · CAPSULE, PELLETS, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Sacubitril" as an intervention, any sponsor and status, largest first.

All 181 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • hypotension11,679
  • death9,164
  • dyspnoea9,055
  • dizziness8,785
  • fatigue8,758
  • cough7,892
  • wrong technique in product usage process7,341
  • weight decreased5,230
  • cardiac failure4,550
  • malaise4,473
  • asthenia3,844
  • weight increased3,520

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20132
20142
2015971
20166,442
20177,878
201812,218
201912,941
202012,382
202116,985
202219,265
202316,689
20244,599
20253,594
20262,216

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Entresto Sprinkle (Sacubitril/Valsartan)

2024 spending

$145K

Beneficiaries

97

173 claims

Per beneficiary

$1,492

$11.25 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$144,718

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 378 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.